1Rosenherg B, van Camp L, Trosko JE, et al. Platinum eom- pounds:a new class of potent antitumour agents [J]. Nature, 1969,222(519 ) :385-386.
2Filipski KK, Loos WJ, Verweij J, et al. Interaction of Cisplatin with the human organic cation transporter 2 [J]. Clin Cancer Res, 2008,14 (12) : 3875-3880.
3Boyer TD. The glutathione S-transferases: an update [J]. Hep- atology, 1989,9(3) :486-496.
4Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs [J] Nat Rev Drug I)iscov,2005,4(4):307-320.
5Yao X, Paniehpisa| K, Kurtzman N, et al. Cisplatin nephrotoxic- ity:a review[J]. Am J Med Sci,2007,334(2) : 115-124.
6Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2 [J]. Am J Pathol,2005,167(6) : 1477-1484.
7Arnesano F, Scintilla S, Natile G. Interaction between platinum eomplexes and a methionine motif found in copper transport proteins [J]. Angew Chem Int Ed Engl, 2007, 46 (47):9062- 9064.
8Ulu R, Dogukan A, Tuzcu M, et al. Regulation of renal organic anion and cation transporters by thyrnoquinone in cisplatin in- duced kidney injury [J]. Food Chem Toxieol, 2012, 50 (5): 1675-1 679.
9Pabla N, Murphy RF, Liu K,et al. The copper transporter Ctr contributes to cisplatin uptake by renal tubular cells during eis platin nephrotoxicity [J]. Am J Physiol Renal Physiol, 2009, 296(3) : F505-511.
10Yonezawa A, Masuda S, Nishihara K, et al. Association be- tween tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat [J]. Biochem Pharmacol, 2005,70 (12) : 1823-1831.
